CoChat

Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

Open access

The DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.

Abstract

Angiopoietin-like protein (ANGPTL)3 regulates plasma lipids by inhibiting LPL and endothelial lipase (EL). ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway and represents a promising therapeutic approach for individuals with homozygous familial hypercholesterolemia due to LDLR mutations. Yet, how ANGPTL3 regulates LDL-C levels is unknown. Here, we demonstrate in hyperlipidemic humans and mice that ANGPTL3 controls VLDL catabolism upstream of LDL. Using kinetic, lipidomic, and biophysical studies, we show that ANGPTL3 inhibition reduces VLDL-lipid content and size, generating remnant particles that are efficiently removed from the circulation. This suggests that ANGPTL3 inhibition lowers LDL-C by limiting LDL particle production. Mechanistically, we discovered that EL is a key mediator of ANGPTL3's novel pathway. Our experiments revealed that, although dispensable in the presence of LDLR, EL-mediated processing of VLDL becomes critical for LDLR-independent particle clearance. In the absence of EL and LDLR, ANGPTL3 inhibition perturbed VLDL catabolism, promoted accumulation of atypical remnants, and failed to reduce LDL-C. Taken together, we uncover ANGPTL3 at the helm of a novel EL-dependent pathway that lowers LDL-C in the absence of LDLR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.ra120000888

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. EL is necessary for the LDLR-independent LDL-C-lowering effect upon ANGPTL3 inhibition. A: Inhibition of ANGPTL3 lowers serum phospholipids in Ldlr−/− mice on chow diet 4 days after ANGPTL3 mAb or control mAb (n = 5 mice per group, 10 mg/kg mAb) (left). Mean ± SEM are shown. P-values are from unpaired two-tailed Student’s t-test. Serum lipid distribution in Ldlr−/− mice showing ANGPTL3 mAb lowers phospholipids across all lipoproteins. Pooled serum [n = 6 mice in control (Ctrl) mAb group; n = 5 mice in ANGPTL3 mAb group] was fractionated by FPLC, and phospholipid levels were measured enzymatically in each fraction (right). B: Serum PLTP activity in Ldlr−/− mice on chow diet 6 days before (baseline) and 7 days after ANGPTL3 mAb or control mAb (n = 6 mice per group, 10 mg/kg mAb). Mean ± SEM are shown. P-values are from two-way ANOVA with Sidak correction posttest relative to control. C: Serum lipid distribution of chow-fed WT (n = 10), Lipg−/− (n = 12), Ldlr−/− (n = 23), and Lipg−/−Ldlr−/− (n = 24) mice (left). Pooled serum from each group of mice was separated by HPLC, and cholesterol levels were measured enzymatically. Ratio showing VLDL and LDL APOB-particle numbers in Ldlr−/− and Lipg−/−Ldlr−/− mice (right). D: Nonfasted serum cholesterol of WT and Lipg−/− mice on chow (baseline), after 2 weeks on HFD (HFD baseline), and 6 days after ANGPTL3 or control mAb dose (25 mg/kg) while on HFD. Mean ± SEM are shown (n = 15 mice in WT Ctrl mAb group, n = 16 mice in all other groups). P-values are from two-way ANOVA with Tukey correction posttest. E: Nonfasted serum lipids of Ldlr−/− and Lipg−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown (n = 14 mice in each Ldlr−/− group, n = 17 mice in Lipg−/−Ldlr−/− Ctrl mAb group, n = 18 mice in Lipg−/−Ldlr−/− ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest.
Fig. 1. EL is necessary for the LDLR-independent LDL-C-lowering effect upon ANGPTL3 inhibition. A: Inhibition of ANGPTL3 lowers serum phospholipids in Ldlr−/− mice on chow diet 4 days after ANGPTL3 mAb or control mAb (n = 5 mice per group, 10 mg/kg mAb) (left). Mean ± SEM are shown. P-values are from unpaired two-tailed Student’s t-test. Serum lipid distribution in Ldlr−/− mice showing ANGPTL3 mAb lowers phospholipids across all lipoproteins. Pooled serum [n = 6 mice in control (Ctrl) mAb group; n = 5 mice in ANGPTL3 mAb group] was fractionated by FPLC, and phospholipid levels were measured enzymatically in each fraction (right). B: Serum PLTP activity in Ldlr−/− mice on chow diet 6 days before (baseline) and 7 days after ANGPTL3 mAb or control mAb (n = 6 mice per group, 10 mg/kg mAb). Mean ± SEM are shown. P-values are from two-way ANOVA with Sidak correction posttest relative to control. C: Serum lipid distribution of chow-fed WT (n = 10), Lipg−/− (n = 12), Ldlr−/− (n = 23), and Lipg−/−Ldlr−/− (n = 24) mice (left). Pooled serum from each group of mice was separated by HPLC, and cholesterol levels were measured enzymatically. Ratio showing VLDL and LDL APOB-particle numbers in Ldlr−/− and Lipg−/−Ldlr−/− mice (right). D: Nonfasted serum cholesterol of WT and Lipg−/− mice on chow (baseline), after 2 weeks on HFD (HFD baseline), and 6 days after ANGPTL3 or control mAb dose (25 mg/kg) while on HFD. Mean ± SEM are shown (n = 15 mice in WT Ctrl mAb group, n = 16 mice in all other groups). P-values are from two-way ANOVA with Tukey correction posttest. E: Nonfasted serum lipids of Ldlr−/− and Lipg−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown (n = 14 mice in each Ldlr−/− group, n = 17 mice in Lipg−/−Ldlr−/− Ctrl mAb group, n = 18 mice in Lipg−/−Ldlr−/− ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest.CC BY · PubMed Central
Fig. 2. Lipidomic analysis reveals the impact of EL on LDL composition. A: Sample preparation for lipidomic analysis. Serum of chow-fed Ldlr−/− and Lipg−/−Ldlr−/− individual mice was collected 7 days after mAb administration and subjected to FPLC analysis to separate lipoproteins. Fractions corresponding to VLDL/LDL/HDL were pooled and snap-frozen for subsequent metabolite extraction. B: Score scatter plot (unsupervised PCA) showing clustering of lipidomics samples depending on lipoprotein species. Model diagnostics: A = 6; R2X = 0.872; Q2X = 0.813. C: Heatmap representing individual metabolites (denoted on the left side) obtained for the comparisons performed in LDL samples (n = 8 mice per group). Heatmap color codes for log2 (fold-change) and unpaired two-tailed Student’s t-test P-values are indicated at the bottom. D: Boxplots (defined in the Materials and Methods) of LDL-lipids upon ANGPTL3 mAb or isotype control. P-values are from unpaired two-tailed Student’s t-test. E: Volcano plots showing impact of ANGPTL3 inhibition on LDL in Ldlr−/− and Lipg−/−Ldlr−/− mice. All mice were on chow diet. See also lipidomics data in supplemental Table S3.
Fig. 2. Lipidomic analysis reveals the impact of EL on LDL composition. A: Sample preparation for lipidomic analysis. Serum of chow-fed Ldlr−/− and Lipg−/−Ldlr−/− individual mice was collected 7 days after mAb administration and subjected to FPLC analysis to separate lipoproteins. Fractions corresponding to VLDL/LDL/HDL were pooled and snap-frozen for subsequent metabolite extraction. B: Score scatter plot (unsupervised PCA) showing clustering of lipidomics samples depending on lipoprotein species. Model diagnostics: A = 6; R2X = 0.872; Q2X = 0.813. C: Heatmap representing individual metabolites (denoted on the left side) obtained for the comparisons performed in LDL samples (n = 8 mice per group). Heatmap color codes for log2 (fold-change) and unpaired two-tailed Student’s t-test P-values are indicated at the bottom. D: Boxplots (defined in the Materials and Methods) of LDL-lipids upon ANGPTL3 mAb or isotype control. P-values are from unpaired two-tailed Student’s t-test. E: Volcano plots showing impact of ANGPTL3 inhibition on LDL in Ldlr−/− and Lipg−/−Ldlr−/− mice. All mice were on chow diet. See also lipidomics data in supplemental Table S3.CC BY · PubMed Central
Fig. 3. EL promotes VLDL catabolism and APOB particle reduction. A: Heatmap of lipidomics analysis, from the study outlined in Fig. 2, representing individual metabolites (denoted on the left side) obtained for the comparisons performed in VLDL samples (n = 8 mice per group). Heatmap color codes for log2 (fold-change) and unpaired two-tailed Student’s t-test P-values are indicated at the bottom. B: Boxplots (defined in the Materials and Methods) of VLDL-lipids upon ANGPTL3 mAb or control antibody treatment. P-values are from unpaired two-tailed Student’s t-test. C: Boxplots (defined in the Materials and Methods) of VLDL-PCs in Ldlr−/− and Lipg−/−Ldlr−/− mice upon ANGPTL3 inhibition. P-values are from unpaired two-tailed Student’s t-test. D: Serum APOB levels before (baseline) and 4 days after ANGPTL3 mAb administration. Mean ± SEM are shown (n = 14 mice in Ldlr−/− groups, n = 18 mice in Lipg−/−Ldlr−/− groups). P-value is from two-way ANOVA with Sidak correction posttest. E: APOB Western blot analysis. Serum of Ldlr−/− (n = 7) and Lipg−/−Ldlr−/− mice (n = 9) was collected 4 days after mAb administration, pooled, and lipoproteins were separated by FPLC. Fractions corresponding to VLDL/LDL were immunoblotted and probed with anti-APOB antibody. Densitometry quantifications are on the right. Samples were derived from the same experiment and gels/blots were processed in parallel. Full scans of Western blots are provided in the supplemental data online. All mice were on chow diet. See also lipidomics data in supplemental Table S4.
Fig. 3. EL promotes VLDL catabolism and APOB particle reduction. A: Heatmap of lipidomics analysis, from the study outlined in Fig. 2, representing individual metabolites (denoted on the left side) obtained for the comparisons performed in VLDL samples (n = 8 mice per group). Heatmap color codes for log2 (fold-change) and unpaired two-tailed Student’s t-test P-values are indicated at the bottom. B: Boxplots (defined in the Materials and Methods) of VLDL-lipids upon ANGPTL3 mAb or control antibody treatment. P-values are from unpaired two-tailed Student’s t-test. C: Boxplots (defined in the Materials and Methods) of VLDL-PCs in Ldlr−/− and Lipg−/−Ldlr−/− mice upon ANGPTL3 inhibition. P-values are from unpaired two-tailed Student’s t-test. D: Serum APOB levels before (baseline) and 4 days after ANGPTL3 mAb administration. Mean ± SEM are shown (n = 14 mice in Ldlr−/− groups, n = 18 mice in Lipg−/−Ldlr−/− groups). P-value is from two-way ANOVA with Sidak correction posttest. E: APOB Western blot analysis. Serum of Ldlr−/− (n = 7) and Lipg−/−Ldlr−/− mice (n = 9) was collected 4 days after mAb administration, pooled, and lipoproteins were separated by FPLC. Fractions corresponding to VLDL/LDL were immunoblotted and probed with anti-APOB antibody. Densitometry quantifications are on the right. Samples were derived from the same experiment and gels/blots were processed in parallel. Full scans of Western blots are provided in the supplemental data online. All mice were on chow diet. See also lipidomics data in supplemental Table S4.CC BY · PubMed Central
Fig. 4. ANGPTL3 inhibition promotes VLDL processing and clearance. A: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) and LDL (right) isolated from Ldlr−/− or Lipg−/−Ldlr−/− mice and injected into Ldlr−/− mice (VLDL from Ldlr−/−: n = 10 recipient mice; VLDL from Lipg−/−Ldlr−/−: n = 9 recipient mice). B: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) or LDL (right) isolated from Apoe−/− mice after 2 weekly injections of ANGPTL3 mAb or control mAb and injected into Apoe−/− mice (n = 10 mice per group). A, B: The percentage of injected CE-label remaining at each timepoint was determined using the value obtained at 30 s as starting point. Mean ± SEM are shown for each timepoint. P-values from two-way ANOVA with Sidak correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001. The half-life was calculated from the decay curve of [3H]CE activity plotted against time. All mice were on chow diet. C, D: NMR analysis of human lipoproteins following ANGPTL3 inhibition with evinacumab (ANGPTL3 mAb). Hyperlipidemic individuals were administered ANGPTL3 mAb or control mAb (phase 1 single ascending dose clinical study) (28), and serum was collected at the indicated timepoints. Mean ± SEM are shown for each timepoint (n = 18 in placebo; n = 10 in 5 mg/kg iv; n = 9 in 10 mg/kg iv; n = 11 in 20 mg/kg iv; n = 12 in 150 mg sc; and n = 9 in 250 mg sc groups). Human VLDL/chylomicron and LDL concentration (C) and particle size analysis by NMR (D). P-values are from two-way ANOVA with Tukey correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to placebo (color of asterisks indicates relevant group); #P < 0.0001 regarding all ANGPTL3 mAb groups relative to placebo; &P < 0.0001 regarding all intravenously administered ANGPTL3 mAb groups relative to placebo.
Fig. 4. ANGPTL3 inhibition promotes VLDL processing and clearance. A: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) and LDL (right) isolated from Ldlr−/− or Lipg−/−Ldlr−/− mice and injected into Ldlr−/− mice (VLDL from Ldlr−/−: n = 10 recipient mice; VLDL from Lipg−/−Ldlr−/−: n = 9 recipient mice). B: Plasma clearance kinetics of [3H]CE-labeled VLDL (left) or LDL (right) isolated from Apoe−/− mice after 2 weekly injections of ANGPTL3 mAb or control mAb and injected into Apoe−/− mice (n = 10 mice per group). A, B: The percentage of injected CE-label remaining at each timepoint was determined using the value obtained at 30 s as starting point. Mean ± SEM are shown for each timepoint. P-values from two-way ANOVA with Sidak correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001. The half-life was calculated from the decay curve of [3H]CE activity plotted against time. All mice were on chow diet. C, D: NMR analysis of human lipoproteins following ANGPTL3 inhibition with evinacumab (ANGPTL3 mAb). Hyperlipidemic individuals were administered ANGPTL3 mAb or control mAb (phase 1 single ascending dose clinical study) (28), and serum was collected at the indicated timepoints. Mean ± SEM are shown for each timepoint (n = 18 in placebo; n = 10 in 5 mg/kg iv; n = 9 in 10 mg/kg iv; n = 11 in 20 mg/kg iv; n = 12 in 150 mg sc; and n = 9 in 250 mg sc groups). Human VLDL/chylomicron and LDL concentration (C) and particle size analysis by NMR (D). P-values are from two-way ANOVA with Tukey correction posttest: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to placebo (color of asterisks indicates relevant group); #P < 0.0001 regarding all ANGPTL3 mAb groups relative to placebo; &P < 0.0001 regarding all intravenously administered ANGPTL3 mAb groups relative to placebo.CC BY · PubMed Central
Fig. 5. ANGPTL3 inhibition lowers LDL-C independently of several lipoprotein receptors. A: Nonfasted serum lipids of Ldlr−/− and Sdc1−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown [n = 7 mice in Sdc1−/−Ldlr−/− control (Ctrl) mAb group, n = 8 mice in all other groups]. P-values are from two-way ANOVA with Sidak correction posttest. HPLC analysis shown at right. B, C: The effect of ANGPTL3 inhibition on serum lipids in ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice on chow diet. Nonfasted serum was collected from Sdc1−/−Ldlr−/− mice (baseline). Scarb1, Scarb1+Lrp1, or control ASOs (25 mg/kg) were administered twice weekly by subcutaneous injections, for a total of 10 doses. Two once-weekly doses of ANGPTL3 or control mAb (10 mg/kg) were administered after first six doses of ASO (ASO pre-mAb). Seven days after the second mAb dose, serum was collected and livers were harvested (ASO, post-mAb). Mean lipid levels ± SEM are shown in B; HPLC analysis of serum is shown in C (n = 8 mice in all groups except n = 7 in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest. D: Hepatic knockdown efficiency upon ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice, corresponding to the study shown in B and C. Mean ± SEM are shown (n = 8 mice per group except n = 7 mice in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from one-way ANOVA with Tukey correction posttest. ****P < 0.0001 for Scarb1 ASO groups or Lrp1+Scarb1 ASO groups relative to control ASO groups.
Fig. 5. ANGPTL3 inhibition lowers LDL-C independently of several lipoprotein receptors. A: Nonfasted serum lipids of Ldlr−/− and Sdc1−/−Ldlr−/− mice on chow diet before (baseline, day −6) and 7 days after ANGPTL3 or control mAb-dose (10 mg/kg). Mean ± SEM are shown [n = 7 mice in Sdc1−/−Ldlr−/− control (Ctrl) mAb group, n = 8 mice in all other groups]. P-values are from two-way ANOVA with Sidak correction posttest. HPLC analysis shown at right. B, C: The effect of ANGPTL3 inhibition on serum lipids in ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice on chow diet. Nonfasted serum was collected from Sdc1−/−Ldlr−/− mice (baseline). Scarb1, Scarb1+Lrp1, or control ASOs (25 mg/kg) were administered twice weekly by subcutaneous injections, for a total of 10 doses. Two once-weekly doses of ANGPTL3 or control mAb (10 mg/kg) were administered after first six doses of ASO (ASO pre-mAb). Seven days after the second mAb dose, serum was collected and livers were harvested (ASO, post-mAb). Mean lipid levels ± SEM are shown in B; HPLC analysis of serum is shown in C (n = 8 mice in all groups except n = 7 in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from two-way ANOVA with Sidak correction posttest. D: Hepatic knockdown efficiency upon ASO-mediated knockdown of Scarb1 and/or Lrp1 in Sdc1−/−Ldlr−/− mice, corresponding to the study shown in B and C. Mean ± SEM are shown (n = 8 mice per group except n = 7 mice in Scarb1+Lrp1 ASO + ANGPTL3 mAb group). P-values are from one-way ANOVA with Tukey correction posttest. ****P < 0.0001 for Scarb1 ASO groups or Lrp1+Scarb1 ASO groups relative to control ASO groups.CC BY · PubMed Central
Fig. 6. ANGPTL3 inhibition lowers LDL-C through VLDL remodeling and remnant clearance. Schematic depicting the mechanism of how ANGPTL3 inhibition lowers LDL-C. Upper panel: During homeostasis, ANGPTL3 curbs vascular lipases LPL and EL and thus regulates APOB-containing lipoprotein turnover. Middle panel: ANGPTL3 inhibition leads to derepression of both lipases, promoting VLDL remodeling and preferential removal of VLDL remnants from the circulation via redundant receptors. ANGPTL3 inhibition hence lowers LDL-C by limiting vascular LDL production. Lower panel: EL is critical in the process: without EL, LDLR-independent clearance mechanisms are perturbed, leading to accumulation of LDL particles and rendering ANGPTL3 inhibition ineffective in the reduction of LDL-C levels.
Fig. 6. ANGPTL3 inhibition lowers LDL-C through VLDL remodeling and remnant clearance. Schematic depicting the mechanism of how ANGPTL3 inhibition lowers LDL-C. Upper panel: During homeostasis, ANGPTL3 curbs vascular lipases LPL and EL and thus regulates APOB-containing lipoprotein turnover. Middle panel: ANGPTL3 inhibition leads to derepression of both lipases, promoting VLDL remodeling and preferential removal of VLDL remnants from the circulation via redundant receptors. ANGPTL3 inhibition hence lowers LDL-C by limiting vascular LDL production. Lower panel: EL is critical in the process: without EL, LDLR-independent clearance mechanisms are perturbed, leading to accumulation of LDL particles and rendering ANGPTL3 inhibition ineffective in the reduction of LDL-C levels.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 210

Metadata

Authors
Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., Van Hout, C., Gromada, J., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V.
Affiliations
  • Regeneron (United States) (US)
  • The University of Texas Southwestern Medical Center (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Gusarova, Viktoria
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2020-09
Volume
61
Issue
9
Pages
1271-1286
ISSN
0022-2275 (ISSN-L)
OpenAlex
W3041635484
Cited by
208
References
69
Citations by year
2026: 34 · 2025: 28 · 2024: 36 · 2023: 29 · 2022: 33 · 2021: 42 · 2020: 6
FWCI
17.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Heart, Lung, and Blood Institute (P01HL020948)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
ANGPTL3, endothelial lipase, VLDL clearance, LDL cholesterol, VLDL remnants, hypercholesterolemia, lipoprotein metabolism, lipidomics
MeSH terms
Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Animals, Female, Humans, Lipase, Cholesterol, LDL, Lipoproteins, VLDL, Male, Receptors, LDL, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. https://app.cochat.ai/papers/10.1194/jlr.ra120000888
The paper
Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., Van Hout, C., Gromada, J., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V. (2020). Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. Journal of Lipid Research. https://doi.org/10.1194/jlr.ra120000888

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.